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Abstract
Introduction: While radical cystectomy is the gold standard for 
muscle-invasive bladder cancer (MIBC), in octogenarians cystec-
tomy results in a higher perioperative mortality rate (6.8‒11.1%) 
than in younger patients (2.2%). Trimodality therapy is a bladder-
sparing regimen composed of transurethral resection of bladder 
tumour (TURBT) and chemoradiotherapy, with intent for salvage 
cystectomy, and has a 62.5‒90% initial complete response rate. 
In this study, we evaluate TURBT and chemoradiotherapy without 
salvage cystectomy in medically inoperable octogenarian patients. 
Methods: We identified a retrospective cohort of patients aged 80‒89 
years with invasive urothelial carcinoma who received combination 
chemoradiotherapy between 2008 and June 2014. Outcomes were 
evaluated by Kaplan-Meier (KM) and Cox regression.
Results: In 40 patients, the mean age was 84.5 years (interquartile 
range [IQR] 83‒86). Seventeen patients received hypofractionated, 
low-dose radiotherapy (LD) (37.5‒40 Gy), while 23 received con-
ventionally fractionated radiotherapy (high-dose [HD]) (50‒65 Gy). 
Mean overall survival (OS) was 20.7 months (IQR 12.75‒23.25), 
while mean recurrence-free survival (RFS) was 13.75 months (IQR 
3.75‒16.5). Patients receiving HD radiotherapy showed improved 
OS and local RFS (LRFS) without significant differences in Grade 
3‒4 toxicities. Univariate Cox regression identified hydroneph-
rosis as a predictor of worse OS and local recurrence and HD 
radiotherapy as a predictor of improved OS and local recurrence 
rates. Multivariate Cox regression identified hydronephrosis to be 
a significant predictor of LRFS.
Conclusions: Primary chemoradiotherapy for inoperable patients 
with MIBC resulted in a three-year OS of 54.9% (comparable to 
cystectomy) and three-year RFS of 42.3%. Superior outcomes were 
associated with more aggressive chemoradiotherapy treatment. The 
results of the local control subanalyses in this study are hypothesis-
generating due to the limited patient numbers in the cohort.
Introduction
Approximately 70 000 people are diagnosed with bladder 
cancer in the U.S. each year1 and 90% of these are urothelial 
carcinomas (UC).2 The gold standard therapy for muscle-
invasive UC is radical cystectomy; however, cystectomy 
bears a Grade 3‒5 complication rate of 13%3 and a perio-
perative mortality of 2.5‒5.2%.3-6 Additionally, periopera-
tive mortality increases with age, increasing from 4.7% in 
patients in their 60s, to 6.8‒11.1% in octogenarians.5,7 Even 
with the additional risks of surgery, population-based evi-
dence suggests local therapy delivered with curative intent 
improves overall survival (OS) and cancer-specific survival 
(CSS) in octogenarians.8
Trimodality therapy (TMT) is an alternative to cystectomy 
comprised of transurethral resection of bladder tumour 
(TURBT), followed by combination chemoradiotherapy, 
with the intention to have the patient undergo salvage cyst-
ectomy if there is local treatment failure. The benefit of com-
bination chemotherapy added to TMT remain unproven, so 
it typically is not included in this treatment approach.9 TMT 
initial complete response (CR) rates vary from approximately 
60‒90%,10-17 with five-year bladder intact survival in these 
studies at 40‒45%,18 and an approximate acute Grade 3/4 
toxicity rate of 36‒46%14,17 and 15.7% during long-term 
followup.17
At the London Regional Cancer Program, combination 
chemoradiotherapy has been offered to medically inoper-
able patients for nearly 20 years. This retrospective study 
sought to evaluate the outcomes of medically inoperable 
octogenarians treated with TMT alone at London Health 
Sciences Centre (LHSC).
Methods 
A comprehensive review of electronic patient charts was 
completed for patients aged 80‒89 year who were deemed 
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medically unsuitable to undergo cystectomy for muscle-
invasive bladder cancer (MIBC) and thus underwent com-
bination chemoradiotherapy as primary therapy for their 
disease. In our centre, with few exceptions, medically 
inoperable patients are treated primarily with chemoradio-
therapy regimens. The selection of the chemotherapy is typ-
ically based upon the patient comorbidities to allow for drug 
tolerance. Low-dose (LD) and high-dose (HD) radiotherapy 
regimens are applied with life-prolonging intent, with both 
protocols having been seen to be able to produce durable 
treatment effects in our centre; we have previously published 
on durable treatment responses using the LD regimen.18 The 
selection of radiotherapy regimen is performed on a case-
by-case basis at the discretion of the treating physician and 
often takes patient general health status into consideration. 
Radiotherapy is applied to the bladder alone, however, in 
cases where there are suspicious lymph nodes on imaging, 
these nodes may be included in the radiation target zone 
at the discretion of the treating physician and on a case-
by-case basis.
Patients evaluated were those who underwent therapy 
between 2008 and June 2014. These dates were chosen 
to ensure complete electronic records at the beginning of 
the period and to allow approximately 12 months of follo-
wup data. Treatment-related toxicities were retrospectively 
assigned according to Common Terminology Criteria for 
Adverse Events (CTCAE) v4.03. Patients with a small-cell 
component were excluded, as were patients who underwent 
salvage cystectomy. Patient survival was censored at record-
ed date of death or last followup. Recurrence was defined as 
the date of first imaging or clinical evidence of either local or 
systemic recurrence. Survival figures are recorded from time 
of diagnosis, while recurrence figures are recorded from the 
date of first treatment administration. Statistical analysis was 




Forty patients met the inclusion criteria and their baseline 
characteristics are summarized in Table 1. The mean age 
of patients was 84.5 year (interquartile range [IQR] 83‒86), 
with 28 males and 12 females. Thirty-five patients had T2 
disease, four had T3, and one had T4 disease, while three 
were node-positive. Thirty-one patients were deemed not to 
be cystectomy candidates due to comorbidity status, while 
others underwent combination therapy due to advanced 
age, patient preference, locally advanced disease, and per-
formance status. All patients underwent a TURBT as both a 
therapeutic and diagnostic procedure, however, only 16 of 
37 patients that had clear documentation as to the extent of 
resection underwent a complete resection.
Patients received one of several treatment regimens, 
encompassing either hypofractionated, LD radiotherapy 
(n=17; 37.5‒40 Gy, 15 fractions, biologically effective dose 
[BED]10=47‒51, BED3=69‒76) or conventionally fraction-
Table 1. Patient and therapy characteristics
Characteristic or treatment Number of patients
Patient total 40
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ECOG:  Eastern Cooperative Oncology Group; FU: fluorouracil; IQR: interquartile range; 
MMC: mitomycin; TUR: transurethral resection.
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ated radiotherapy (HD) (n=23; 50‒65 Gy, 20‒33 fractions, 
BED10=63‒77, BED3=92‒105). One of three sensitizing 
chemotherapy regimens were used; carboplatin alone, 
cisplatin alone, or 5-fluorouracil (5-FU) and mitomycin C 
(MMC). Given the fact that the hypofractionated regimens 
were associated with a lower BED, we refer to these regi-
mens as low-dose (LD), and the conventionally fraction-
ated regimens as high-dose (HD). A commonly employed 
strategy was LD radiotherapy with carboplatin, as our early 
experience suggested this treatment was well-tolerated and 
effective in this patient population19 and 16 patients received 
this combination. 
Treatment-related toxicities and delayed hematuria
Retrospectively assessed treatment-related acute toxicities 
are summarized in Table 2. Nine Grade 3‒5 toxicities in 
patients were recorded — four of these were related to pain 
and one to cellulitis, none of which were life-threatening. 
Life-threatening toxicities included one patient who died of 
sepsis while on therapy and one patient who had a myo-
cardial infarction. There were only three Grade 3-4 gen-
itourinary (GU) toxicities and no gastrointestinal (GI) tox-
icities. The most common late toxicity documented was 
hematuria (n=13), with the majority being associated with 
local recurrence (n=11), and nine of these being Grade 3‒4 
(Supplementary Table 1; available at www.cuaj.ca). Of the 
two patients with late bleeding without recurrence (and thus 
likely attributable to the radiotherapy), the toxicity were 
Grades 1 and 3, respectively.
Overall patient outcomes
Objective complete response to therapy, as defined by no 
visible tumour seen on cystoscopy, was seen in 24 of the 31 
(77.4%) patients who underwent a surveillance cystoscopy 
within four months of therapy completion. Imaging studies 
were completed at the discretion of the clinical team. Patient 
outcomes are summarized in Figs.1, 2, 3. The three-year OS 
was 54.9% (Fig. 1) and 11/14 patients died of their disease. 
The three-year recurrence-free survival (RFS) was 42.3% 
(Supplementary Fig. 1; available at www.cuaj.ca), while the 
three-year local RFS (LRFS) was 48.7% (Fig. 2). Disease relapse 
was typically managed with palliative chemotherapy or sup-
portive measures; salvage cystectomy was not performed.
Subgroup analysis
Chemotherapy regimens were divided into carboplatin 
and “non-carbo (NC)” chemotherapies, which included 
cisplatin and 5-FU and MMC. There was no difference in 
complete response rates between chemotherapy regimens 
(Supplementary Table 2; available at www.cuaj.ca; Fisher 
exact test [FET]). Using Kaplan-Meier survival analysis, 
NC chemotherapy regimens were found to be associated 
with improved OS by log-rank test (Fig. 3; p=0.0425). NC 
chemotherapies also showed a non-significant trend towards 
improvement in LRFS (Supplementary Fig. 2; available at 
www.cuaj.ca; p=0.1119). Finally, there was a non-signifi-
cant trend towards higher rates of Grade 1‒2 and 3‒5 tox-
icities in patients who received carboplatin (Supplementary 
Table 3; available at www.cuaj.ca).    
Radiation therapy was divided into LD radiotherapy 
(37.5‒40 Gy) and HD radiotherapy (50‒65 Gy). There was 
no difference in complete response rates between radiother-
apy regimens (Supplementary Table 2). HD radiotherapy 
was found to show an improvement in both OS (p=0.0348) 
and LRFS (p=0.0367) by log-rank test (Figs. 4, 5). The HD 
radiotherapy group did show a higher rate (20/23 vs. 7/17) 
of Grade 1‒2 toxicities vs. the LD radiotherapy group (Table 
3), however, there were no significant differences in the rates 
of local regional GI or GU Grade 3‒4 toxicities or in the 
overall rate of delayed hematuria (Table 3).
Finally, outcomes were analyzed by chemoradiotherapy 
regimen. Although limited by the small numbers in each 
group, the HD, NC group showed a non-significant trend 
towards improved OS (Fig. 6) and LRFS (Supplementary Fig. 
3; available at www.cuaj.ca) when compared with the HD 
and carboplatin, LD and carboplatin, and LD NC groups.
Cox regression analysis
Univariate Cox regression analysis was completed to evalu-
ate the contribution of clinical factors to OS and LRFS. 
Table 2. Acute toxicities assessed by Common Terminology Criteria for Adverse Events (CTCAE), version 4.03
Grade GI GU Cardiovascular Infectious Respiratory Renal Other Total
1 15 15 2 0 1 1 4 38
2 1 4 0 0 0 0 5 11
3 0 3 1 1 0 0 2 6
4 0 0 1 0 0 0 0 1
5 0 0 0 1 0 0 0 1
Total 16 22 4 2 1 1 11 58
Total Grade 3–5 0 3 2 2 0 0 2 9
GI: gastrointestinal; GU: genitourinary.
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Hydronephrosis (hazard ratio [HR] 3.13, 95% confidence 
interval [CI] 1.10‒8.92) and HD radiotherapy (HR 0.34, 95% 
CI 0.12‒0.97) were significant predictors of OS (Table 4), 
while hydronephrosis (HR 4.67, 95% CI 1.53‒14.31) and 
HD radiotherapy (HR 0.35, 95% CI 0.13‒0.99) were signifi-
cant predictors of LRFS (Table 5).
Multivariate Cox regression was also completed using 
the variables that were found to be statistically significant 
on univariate analysis. This found only a trend towards 
significance for both hydronephrosis and HD radiotherapy 
in OS (Table 4), while hydronephrosis (HR 3.95, 95% CI 
1.29‒12.1) was a predictor of LRFS (Table 5).
Discussion
In this retrospective review of 40 patients aged 80‒89 years 
(mean 84.5) who were medically inoperable for MIBC and 
treated with chemoradiotherapy, the three-year OS, RFS, 
and LRFS were 54.9%, 42.3%, and 48.7%, respectively. 
The historical results of radical cystectomy, indicate five-
year OS and LRFS figures of 40‒60% and 80‒90%, respect-
ively.18 Octogenarians have a median survival of only 3.3 
years following radical cystectomy, compared with 7.7 years 
for their younger counterparts, and have a 42.3% five-year 
cumulative death rate from other causes.5 Thus, our three-
year OS outcomes are comparable for reported survival for 
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Fig. 2. Overall cohort: Kaplan-Meier local recurrence-free survival.
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for long-term disease control in this patient population is less 
stringent due to the lower median survival time.
Radical cystectomy bears significant morbidity and mor-
tality, with an overall perioperative complication rate of 
28‒49%,3,4 and a Grade 3‒5 complication rate of approxi-
mately 13%.3-6 Additionally, perioperative mortality rates 
rise in octogenarians,5 and while overall Grade 3‒5 compli-
cations are similar, one study identified a significant increase 
in cardiovascular (9.5‒19.7%) and neurological (3.9‒10.3%) 
complications.5 In our study, there were nine Grade 3‒5 
acute toxicities (22.5%), with one patient who died from 
sepsis while on treatment (2.5%) and one who suffered a 
non-fatal myocardial infarction. Acute Grade 1‒2 GU (19; 
47.5%) and GI (16; 40%) toxicities were common, while 
severe late toxicities were uncommon, with only two patients 
experiencing late treatment-related hematuria, of which one 
patient had Grade 1 toxicity and the other Grade 3 (11 had 
late bleeding related to tumour recurrence). Therefore, the 
octogenarian mortality rate in our study was lower than that 
in the cystectomy literature (2.5% vs. 6.8‒11.1%),5 while 
there was an increased rate of Grade 3‒5 complications; 
most, however, were non-life-threatening.
In this study, the choice of chemotherapy regimen was 
associated with improved OS, but not LRFS. Carboplatin 
may have been given to patients with multiple comorbid-
ities, reduced performance status, and/or impaired renal 
function precluding the use of cisplatin; therefore, this 
may represent a selection bias. For example, patients with 
hydronephrosis, an adverse prognostic factor, may be more 
likely to receive carboplatin because of impaired renal func-
tion. That said, a phase 3 study of 360 patients given 5-FU 
and MMC showed a 13% improvement in both two-year 
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Fig. 6. Kaplan-Meier overall survival analysis by chemoradiotherapy regimen.








Hydronephrosis 3.13 1.10–8.92 0.0339*
Complete TUR 0.89 0.31–2.55 0.8256
Cardiovascular disease 2.63 0.91–7.63 0.0749
Respiratory disease 1.54 0.52–4.58 0.4493
Diabetes 0.30 0.04–2.25 0.1644
Nodal disease 1.30 0.17–9.89 0.8106
High-dose radiation 0.34 0.12–0.97 0.0457*
Non-carbo 0.16 0.02–1.22 0.0786
Multivariable analysis
Hydronephrosis 2.82 0.98–8.15 0.0569
High-dose radiation 0.41 0.14–1.21 0.1072
*Statistically significant. TUR: transurethral resection.




























FET: Fisher exact test.
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vs. radiotherapy alone17 and may be a more appropriate 
alternative to carboplatin when cisplatin regimens are not 
tolerated. However, the approximate four weeks required 
to fully deliver this chemotherapy regimen would limit its 
applicability in patients selected for shorter-term, LD radio-
therapy regimens.
LD radiotherapy with platinum chemosensitization has 
been administered in our centre in order to provide disease 
control while minimizing toxicity and overall treatment 
time in frail patients, as previously reported.19 In this current 
study, while a reduced low-grade toxicity was noted in the 
LD radiotherapy group, outcomes in terms of OS and LRFS 
were inferior, while there was no difference in the number 
of Grade 3‒4 toxicities or hematuria. This corresponds with 
the result of a 2006 Dutch study, which showed that 10 Gy 
increments in the final radiotherapy dose increased the local 
control rate by 50% in three years.20,21 Notably, while there 
is evidence regarding the overall radiation dose, studies have 
shown no effect of the number of fractions or duration of 
treatment on local control, and thus hypofractionated (55 
Gy/20 fractions) gives comparable results to conventionally 
fractionated (62 Gy/32 fractions) radiotherapy.21,22
This study has a number of potential limitations. It is 
a retrospective analysis with a limited number of hetero-
geneously treated patients, limiting its statistical power. All 
outcomes, including adverse events, recurrence, and death 
were assessed retrospectively, and causality of adverse 
events was inferred from the available clinical documen-
tation, with variable number of followup visits surround-
ing therapy. Recurrence and death were determined from 
imaging tests and clinical notes, and not all patients under-
went a post-treatment cystoscopy for assessment of tumour 
response. Finally, no adjustment was made in the Cox regres-
sion analysis to account for multiple comparisons due to the 
limited sample size of our study. Thus, we acknowledge that 
the results are primarily hypothesis-generating. 
However, the results are consistent with conclusions that 
chemoradiotherapy is a safe treatment option for MIBC in 
octogenarians and is associated with three-year OS and 
RFS rates of 54.9% and 42.3%, respectively in our cohort. 
Based on our experience and reports of prospective trials, 
our results with TMT comprised of TURBT followed by hyp-
ofractionated HD radiotherapy (55 Gy/20 fractions) with 
concurrent 5-FU and MMC, as described in the study by 
James et al in 201217 appear to provide an appropriate bal-
ance between risk of toxicity and optimizing clinical out-
comes in suitable octogenarians. 
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